Skip to main content

Table 4 The effect of VAP on clinical outcomes in study patients

From: The effect of parenteral selenium on outcomes of mechanically ventilated patients following sepsis: a prospective randomized clinical trial

Outcome (s) Early VAP OR [95 % CI] P Late VAP OR [95 % CI] P value
Yes No Yes No
DOMV, mean ± SD 10.6 ± 4 8.6 ± 5.5   0.17 13.3 ± 1.4 8.2 ± 4.8   <0.0001
Duration of ICU stay, mean ± SD 22.9 ± 15.5 20 ± 17.9   0.54 33 ± 17 16.5 ± 13.4   <0.0001
Duration of hospital stay, mean ± SD 25.5 ± 17 24 ± 23   0.78 37 ± 22 19.3 ± 15.6   0.002
Days on vasopressor therapy, mean ± SD 3.4 ± 4 5.5 ± 5   0.13 8.3 ± 5.3 2.4 ± 3   <0.0001
Incidence of new infection, n/N 8/33 8/21 0.6 [0.18–2] 0.60 13/19 3/35 46 [8–259] <0.0001
Incidence of ARDS, n/N 3/33 4/21 0.57 [0.11–2.8] 0.47 4/19 3/35 3.9 [0.76–20] 0.087
Overall mortality, n/N 16/33 13/21 0.97 [0.33–2.8] 0.54 14/19 15/35 10 [1.8–47] 0.001
  1. DOMV duration of mechanical ventilation, ICU intensive care unit, VAP ventilator-associated pneumonia, ARDS acute respiratory distress syndrome, SD standard deviation, OR odds ratio